登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603207 证券简称：小方制药 公告编号:2025-046 上海小方制药股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事会秘书兼财务负责人：罗晓旭 独立董事：余玮 会议召开时间：2025年12月09日（星期二）11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年12月02日（星期二）至12月08日（星期一）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱info@xf-pharma.com进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 上海小方制药股份有限公司（以下简称"公司"）已于2025年10月25日发布公司2025年第三季度报告，为 便于广大投资者更全面深入地了解公司2025年第三季度经营成果、财务状况，公司 ...

上海小方制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603207 证券简称：小方制药 公告编号:2025-046 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 12 月 02 日（星期二）至 12 月 08 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 info@xf-pharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 上海小方制药股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发布公司 2025 年第三季度报告，为便于广大投资者更全 面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划 于 2025 年 12 月 09 日（星期二）11:00-12:00 举行 2025 年第三季度 业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...

Core Viewpoint - The stock of Xiaofang Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 4.826 billion yuan, while the company has shown a year-to-date stock price increase of 16.11% [1] Group 1: Stock Performance - As of November 19, Xiaofang Pharmaceutical's stock price is 30.06 yuan per share, with a trading volume of 24.9066 million yuan and a turnover rate of 1.51% [1] - The stock has seen a decline of 6.12% over the last five trading days, 7.90% over the last 20 days, and 16.50% over the last 60 days [1] - The company has appeared on the "龙虎榜" (a stock trading list) eight times this year, with the most recent appearance on August 4, where it recorded a net buy of 3.9196 million yuan [1] Group 2: Financial Performance - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, representing a year-on-year growth of 8.17%, and a net profit attributable to shareholders of 170 million yuan, up 5.09% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 353 million yuan [3] Group 3: Shareholder Information - As of November 10, the number of shareholders of Xiaofang Pharmaceutical is 13,700, an increase of 2.88% from the previous period, with an average of 3,956 circulating shares per shareholder, a decrease of 2.80% [2] - The ninth largest circulating shareholder is Guangfa Multi-Dimensional Emerging Stock (003745), holding 753,100 shares as a new shareholder, while several funds have exited the top ten circulating shareholders [3] Group 4: Business Overview - Xiaofang Pharmaceutical, established on August 12, 1993, is located in Fengxian District, Shanghai, and specializes in the research, production, and sales of external-use medications [1] - The company's main business revenue composition includes digestive medications (51.05%), skin medications (39.79%), and ear, nose, and throat medications (9.08%) [1]

Core Insights - Xiaofang Pharmaceutical experienced a 3.13% decline in stock price on November 17, with a trading volume of 80.09 million yuan [1] - The company reported a financing net purchase of 2.84 million yuan on the same day, with a total financing balance of 92.34 million yuan, representing 5.55% of its market capitalization [1] - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, reflecting a year-on-year growth of 8.17% [2] Financing and Trading Activity - On November 17, Xiaofang Pharmaceutical had a financing buy amount of 7.44 million yuan and a financing repayment of 4.60 million yuan, resulting in a net financing purchase of 2.84 million yuan [1] - The total financing balance of 92.34 million yuan is above the 50th percentile level over the past year, indicating a relatively high level of financing activity [1] - The company had no short selling activity on November 17, with a short selling balance of 0.00 yuan, which is at the 90th percentile level over the past year [1] Company Performance - Xiaofang Pharmaceutical's main business revenue composition includes digestive products (51.05%), skin products (39.79%), and ear, nose, and throat products (9.08%) [1] - As of November 10, the number of shareholders increased by 2.88% to 13,700, while the average circulating shares per person decreased by 2.80% to 3,956 shares [2] - Cumulatively, the company has distributed 353 million yuan in dividends since its A-share listing [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders include a new entrant, GF Multi-Dimensional Emerging Stock (003745), holding 753,100 shares [3] - Notably, CITIC Securities' mixed funds have exited the top ten circulating shareholders list [3]

Core Insights - The company Xiaofang Pharmaceutical (603207) reported that as of November 10, 2025, the number of shareholders is 13,749 [1] Company Information - Xiaofang Pharmaceutical is actively engaging with investors through platforms to provide updates on shareholder statistics [1]

Core Points - Shanghai Xiaofang Pharmaceutical Co., Ltd. has announced a change in the continuous supervision sponsor representative for its initial public offering (IPO) project [1] - The original representatives, Chen Zhenyu and Liu Yaxin, will be succeeded by Chen Sheng due to Chen Zhenyu's work relocation [1] - The change will not affect the ongoing supervision work by Guosen Securities [1] Summary by Sections Company Announcement - The board of directors of Shanghai Xiaofang Pharmaceutical guarantees the truthfulness, accuracy, and completeness of the announcement [1] - Guosen Securities has issued a letter regarding the designation of the continuous supervision sponsor representative for the company's IPO [1] Personnel Changes - Chen Zhenyu will no longer serve as the continuous supervision sponsor representative due to work changes [1] - Chen Sheng has been appointed to replace Chen Zhenyu, alongside Liu Yaxin, as the new representatives for the IPO project [1] Acknowledgment - The board expresses gratitude for Chen Zhenyu's contributions during his tenure as the sponsor representative [1]

保荐代表人陈振瑜先生因工作变动原因，不再担任公司持续督导的保荐代 表人。为保证持续督导工作的有序进行，国信证券决定委派陈圣先生（简历见 附件）接替陈振瑜先生担任公司首次公开发行股票项目持续督导的保荐代表人。 本次变更后，公司首次公开发行股票项目持续督导的保荐代表人为刘雅昕 先生和陈圣先生。本次变更不影响国信证券对公司的持续督导工作，公司董事 会对陈振瑜先生在担任公司保荐代表人期间做出的贡献表示衷心感谢！ 特此公告。 上海小方制药股份有限公司董事会 2025 年 11 月 15 日 附件： 证券代码：603207 证券简称：小方制药 公告编号：2025-045 上海小方制药股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海小方制药股份有限公司（以下简称"公司"）于近日收到保荐机构国信 证券股份有限公司（以下简称"国信证券"）出具的《国信证券股份有限公司关 于指定上海小方制药股份有限公司首次公开发行股票持续督导保荐代表人的函》。 国信证券作为公司首次公开发行股票的保荐机构，原指 ...

Core Viewpoint - The financial performance and stock activity of Xiaofang Pharmaceutical indicate a stable growth trajectory, with a slight increase in revenue and net profit, while the financing situation remains relatively low compared to historical levels [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, representing a year-on-year growth of 8.17% [2]. - The net profit attributable to the parent company for the same period was 170 million yuan, reflecting a year-on-year increase of 5.09% [2]. Group 2: Stock and Financing Activity - On November 11, Xiaofang Pharmaceutical's stock price increased by 0.09%, with a trading volume of 23.27 million yuan [1]. - The financing buy-in amount on the same day was 2.76 million yuan, while the financing repayment was 1.95 million yuan, resulting in a net financing buy-in of 816,500 yuan [1]. - The total financing and securities lending balance as of November 11 was 89.99 million yuan, which accounts for 5.16% of the circulating market value, indicating a low financing balance compared to the past year [1]. - There were no securities lent or sold on November 11, with the securities lending balance remaining at zero, which is at a high level compared to the past year [1]. Group 3: Shareholder Information - As of October 31, the number of shareholders for Xiaofang Pharmaceutical was 13,400, an increase of 0.31% from the previous period [2]. - The average number of circulating shares per shareholder was 4,070, which decreased by 0.31% compared to the previous period [2]. - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends [3].

Core Points - Zhang Changwei submitted a written resignation report to the company's board on November 10, 2025, due to adjustments in the company's governance structure [1] - The company held a staff representative meeting on the same day to elect Yin Yufeng as the employee representative director [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海小方制药股份有限公司（以下简称"公司"）董事会于2025年11月10日 收到张长伟先生提交的书面辞职报告。因公司治理结构调整，张长伟先生申请辞 去公司第二届董事会非独立董事职务。公司于同日召开职工代表大会暨第二届职 工代表董事选举大会选举尹毓峰先生为职工代表董事。现将相关情况公告如下： 证券代码：603207 证券简称：小方制药 公告编号：2025-044 上海小方制药股份有限公司 关于公司董事离任暨选举职工代表董事的公告 上海小方制药股份有限公司董事会 2025年11月11日 (一) 提前离任的基本情况 二、选举职工代表董事的情况 根据《公司法》《公司章程》的有关规定，公司于2025年11月10日召开职工 代表大会，选举尹毓峰先生（简历详见附件）担任公司第二届董事会职工代表 董事，任期自本次职工代表大会选举通过之日起至公司第二届董事会任期届满 之日止。 尹毓峰先生当选公司职工代表董事后，公司第二届董事会兼任公司高级管 理人员以及由职工代表担任的董事人数总计未超过公司董事总数 ...